Identification and Characterization of a New Tubulin-Binding Tetrasubstituted Brominated Pyrrole
- Susan L. Mooberry,
- Kimberly N. Weiderhold,
- Sivanesan Dakshanamurthy,
- Ernest Hamel,
- Edith J. Banner,
- Anastasia Kharlamova,
- Jonathan Hempel,
- John T. Gupton and
- Milton L. Brown
- Department of Physiology and Medicine, Southwest Foundation for Biomedical Research, San Antonio, Texas (S.L.M., K.N.W.); Lombardi Comprehensive Cancer Center, Drug Discovery Program, Department of Oncology, Georgetown University Medical Center, Washington DC (S.D., M.L.B.); Toxicology and Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland (E.H.); and Department of Chemistry, Gottwald Center for the Sciences, University of Richmond, Richmond, Virginia (E.J.B., A.K., J.H., J.T.G.)
- Address correspondence to:
Dr. Susan L. Mooberry, Department of Physiology and Medicine, Southwest Foundation for Biomedical Research, P.O. Box 760549, San Antonio, Texas 78245-0549. E-mail: smooberry{at}sfbr.org
Abstract
We studied the mechanism of action of 3,5-dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid ethyl ester (JG-03-14) and found that it is a potent microtubule depolymerizer. JG-03-14 caused a dose-dependent loss of cellular microtubules, formation of aberrant mitotic spindles, accumulation of cells in the G2/M phase of the cell cycle, and Bcl-2 phosphorylation. These events culminated in the initiation of apoptosis, as evidenced by the caspase 3-dependent cleavage of poly(ADP-ribose) polymerase (PARP). JG-03-14 has antiproliferative activity against a wide range of cancer cell lines, with an average IC50 value of 62 nM, and it is a poor substrate for transport by P-glycoprotein. JG-03-14 inhibited the polymerization of purified tubulin in vitro, consistent with a direct interaction between the compound and tubulin. JG-03-14 potently inhibited the binding of [3H]colchicine to tubulin, suggesting that it bound to tubulin at a site overlapping the colchicine site. JG-03-14 had antitumor effects in the PC3 xenograft model, in which it caused greater than 50% reduction in tumor burden after 14 days of treatment. Molecular modeling studies indicated that the dimethoxyphenyl group of JG-03-14 occupies a space similar to that of the trimethoxyphenyl group of colchicine. However, the 2,3,5-trisubstituted pyrrole group, which is connected to the dimethoxyphenyl moiety, interacted with both α and β tubulin in space not shared with colchicine, suggesting significant differences compared with colchicine in the mechanism of binding to tubulin. Our results suggest that this tetransubstituted pyrrole represents a new, biologically active chemotype for the colchicine site on tubulin.
Footnotes
-
This work was supported by grants from the William Randolph Hearst Foundation, the Amon Carter Foundation (to S.L.M.) and the National Institutes of Health Area Program R15-CA67236 (to J.T.G.).
-
ABBREVIATIONS: 2ME2, 2-methoxyestradiol; Pgp, P-glycoprotein; PDB, Protein Database; DMA-colchicine, N-deacetyl-N-(2-mercaptoacetyl)-colchicine; RMSD, root mean square difference; MD, molecular dynamics; FBS, fetal bovine serum; SRB, sulforhodamine B; RR, relative resistance; PARP, poly(ADP-ribose) polymerase; DMSO, dimethyl sulfoxide; R123, rhodamine 123; DiOC2(3), 3′-diethyloxacarbocyanine iodide; NCI, National Cancer Institute.
-
- Received February 6, 2007.
- Accepted April 17, 2007.
- The American Society for Pharmacology and Experimental Therapeutics



